Genecast Hopes for High IPO Valuation Despite Red Ink, Regulatory Risk
The maker of cancer diagnostics and testing products has made a second filing for a Hong Kong IPO, even as its industry faces regulatory risk due to the newness of…
RELATED ARTICLES
-
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
- Fortior hopes to ride China chip wave to high valuation
-
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK
-
Vanke bleeds red ink but detects signs of upturn
2202.HK 000002.SHE
- Dalu chases rich valuation on high margins in weak real estate market
- Baige flies into IPO on demand for its popular – but costly – insurance risk services
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
